The medical management of menopause: A four-country comparison care in urban areas

Maturitas

Volumn 59, Issue 1, 2008, Pages 7-21

  Sievert, Lynnette Leidy ^a   Saliba, Matilda ^b   Reher, David ^c   Sahel, Amina ^d   Hoyer, Doris ^e   Deeb, Mary ^b   Obermeyer, Carla Makhlouf ^f  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Institut National d'Administration Sanitaire Morocco   (Morocco)

^e Fallon Clinic   (United States)

^f HARVARD UNIVERSITY   (United States)

Author keywords

Hormone therapy; Lebanon; Medicalization; Menopause; Morocco; Physician prescribing practices; Spain; United States

Indexed keywords

ADULT; ARTICLE; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INCOME; LEBANON; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL PRACTICE; MENOPAUSE; PHYSICIAN ATTITUDE; PRESCRIPTION; SPAIN; URBAN POPULATION;

BIOPSY; BONE DENSITY; DECISION MAKING; ENDOMETRIUM; FEMALE; HEALTH CARE SURVEYS; HORMONE REPLACEMENT THERAPY; HUMANS; LEBANON; MAMMOGRAPHY; MASSACHUSETTS; MENOPAUSE; MIDDLE AGED; MOROCCO; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; SPAIN; SPECIALTIES, MEDICAL; URBAN HEALTH SERVICES; URBAN POPULATION;

EID: 38749118224     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.11.001     Document Type: Article

References (56)

1. Zola I.K. Medicine as an institution of social control. Sociol Rev 20 (1972) 487-504
2. Meyer V.F. Medicalized menopause, U.S. style. Health Care Women Int 24 (2003) 822-830
3. Watkins E.S. The medicalization of male menopause in America. Soc History Med 20 2 (2007) 369-388
4. Bernis C., and Reher D.S. Environmental contexts of menopause in Spain: comparative results from recent research. Menopause 14 (2007) 777-787
5. Conrad P. The shifting engines of medicalization. J Health Soc Behav 46 (2005) 3-14
6. Conrad P., and Leiter V. Medicalization, markets, and consumers. J Health Soc Behav 45 1 (2004) 158-176
7. Griffiths F. Women's control and choice regarding HRT. Soc Sci Med 49 (1999) 469-481
8. Purdy L. Medicalization, medical necessity and feminist medicine. Bioethics 15 (2001) 248-261
9. McCrea F.B. The politics of menopause: the 'discovery' of a deficiency disease. Soc Probl 31 (1983) 111-123
10. Palmlund I. The social construction of menopause as risk. J Psychosom Obstet Gynecol 18 (1997) 87-94
11. Sievert L.L. The medicalization of female fertility: points of significance for the study of menopause. Coll Antropol 27 (2003) 67-78
12. Worcester N., and Whatley M.H. The selling of HRT: playing on the fear factor. Feminist Rev 41 (1992) 1-26
13. Wilson R.A. Feminine forever (1966), Evans, NY
14. Kennedy D.L., Baum C., and Forbes M.B. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 65 (1985) 441-446
15. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117 (1992) 1048-1051
16. Manson J.E., et al. Estrogen plus progestin and the risk of coronary heart disease. NEJM 349 (2003) 523-534
17. Shumaker S., Legault C., Rapp S., et al. The effects of estrogen plus progestin on the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA 289 (2003) 2651-2662
18. Wassertheil-Smoller S., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
19. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
20. Ena G., Rozenberg S., and Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Human Reprod 18 11 (2003) 2245-2248
21. Klaiber E.L., Vogel W., and Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 84 (2005) 1589-1601
22. Power M.L., Schulkin J., and Rossouw J.E. Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists. Menopause 14 1 (2007) 20-28
23. Power M.L., Zinberg S., and Schulkin J. A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 13 3 (2006) 434-441
24. Blumel J.E., Castelo-Branco C., Chedraui P.A., et al. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 11 1 (2004) 57-61
25. Buist D.S.M., Newton K.M., Miglioretti D.L., et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104 (2004) 1042-1050
26. Heitmann C., Greiser E., and Doren M. The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 12 4 (2005) 405-411
27. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 1 (2004) 47-53
28. Morabia A., and Costanza M.C. Recent reversal of trends in hormone therapy use in a European population. Menopause 13 1 (2006) 111-115
29. NAMS. Position statement: estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 14 2 (2007) 168-182
30. Jolleys J.V., and Olesen F. A comparative study of prescribing of hormone therapy in US and Europe. Maturitas 23 (1996) 46-53
31. Ringa V., Legare F., Dodin S., Norton J., Godin G., and Breart G. Hormone therapy prescription among physicians in France and Quebec. Menopause 11 1 (2004) 89-97
32. Rozenberg S.C., Fellemans C., Kroll M., and Vandromme J. The menopause in Europe. Int J Fertil Women Med 45 (2000) 182-189
33. World Bank. Kingdom of Morocco, poverty update, vol. 1: main report, report no. 21506-MOR. Middle East and North Africa, Human Development Sector (MNSHD); March 30, 2001.
34. Obermeyer C.M., Reher D., and Saliba M. Symptoms, menopausal status, and country differences: a comparative analysis from the DAMeS project. Menopause 14 (2007) 788-797
35. Obermeyer C.M., Reher D., Cortes Alcala L., and Price K. The menopause in Spain: results of the DAMES (Decisions At Menopause) Study. Maturitas 52 (2005) 190-198
36. Obermeyer C.M., Reynolds R.F., Price K., and Abraham A. Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause 11 4 (2004) 456-465
37. Obermeyer C.M., Schulein M., Hajji N., and Azelmat M. Menopause in Morocco: symptomatology and medical management. Maturitas 41 (2002) 87-95
38. Obermeyer C.M., Ghorayeb F., and Reynolds R. Symptom reporting around the menopause in Beirut, Lebanon. Maturitas 33 (1999) 249-258
39. Kassak K.M., Ghomrawi H.M.K., Osseiran A.M.A., and Kobeissi H. The providers of health services in Lebanon: a survey of physicians. Human Resourc Health 4 4 (2006). http://www.human-resources-health.com/content/4/1/4 [open access article: http://www.human-resources-health.com/content/4/1/4]
40. El-Kak F., Jurdi R., Kaddour A., and Zurayk H. Gender and sexual health in clinical practice in Lebanon. Int J Gynecol Obstet 87 (2004) 260-266
41. Hovi S.-L., Karttunen T., Karro H., and Hemminki E. Comparison of Estonian and Finnish physicians' opinions of menopause and hormone therapy. Maturitas 49 (2004) 107-113
42. Obermeyer C.M., Sahel A., Hajji N., and Schulein M. Physicians' perceptions of menopause and prescribing practices in Morocco. Int J Gynecol Obstet 73 (2001) 47-55
43. Castelo-Branco C., Ferrer J., Palacios S., and Cornago S. The prescription of hormone replacement therapy in Spain: differences between general practitioners and gynaecologists. Maturitas 55 (2006) 308-316
44. Mueller K.A., Sanchez G.J.Z., and Sievert L.L. Sources of information and HRT prescribing practices among gynecologists in Puebla, Mexico. Maturitas 45 (2003) 137-144
45. Exline J.L., Siegler I.C., and Bastian L.A. Differences in providers' beliefs about benefits and risks of hormone replacement therapy in managed care. J Women's Health 7 7 (1998) 879-884
46. Mort E.A. Clinical decision-making in the face of scientific uncertainty: hormone replacement therapy as an example. J Family Practice 42 2 (1996) 147-151
47. Newton K.M., LaCroix A.Z., Buist D.S.M., Anderson L.A., and Delaney K. What factors account for hormone replacement therapy prescribing frequence?. Maturitas 39 1 (2001) 1-10
48. Seto T.B., Taira D.A., Davis R.B., Safran C., and Phillips R.S. Effect of physician gender on the prescription of estrogen replacement therapy. J Gen Intern Med 11 4 (1996) 197-203
49. Rolnick S.J., Kopher R.A., Compo R.B., Kelley M.E., and DeFor T.A. Provider attitudes and self-reported behaviors related to hormone replacement therapy. Menopause 6 3 (1999) 257-263
50. Carda S.N., Bilge S.A., Ozturk T.N., Oya G., Ece O., and Hamiyet B. The menopausal age, related factors and climacteric symptoms in Turkish women. Maturitas 30 (1998) 37-40
51. Elinson L., Cohen M.M., and Elmslie T. Hormone replacement therapy: a survey of Ontario physicians' prescribing practices. J Can Med Assoc 161 6 (1999) 695-698
52. Nassar A.H., Essamad H.M.A., Awwad J.T., Khoury N.G., and Usta I.M. Gynecologists' attitudes towards hormone therapy in the post "Women's Heath Initiative" study era. Maturitas 52 (2005) 18-25
53. Lock M. Encounters with aging: mythologies of menopause in Japan and North America (1993), University of California Press, Berkeley, CA
54. Kaufert P.A., and Lock M. Medicalization of women's third age. J Psychosom Obstet Gynecol 18 (1997) 81-86
55. Payer L. Medicine and culture: varieties of treatment in the United States, England, West Germany, and France (1988), Henry Holt and Company, New York
56. Barsky A.J., and Borus J.F. Somatization and medicalization in the era of managed care. JAMA 274 (1995) 1931-1934